COMBI Stock Overview
Engages in the development of gene therapy for severe life-altering diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CombiGene AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.58 |
| 52 Week High | SEK 4.30 |
| 52 Week Low | SEK 1.27 |
| Beta | 1.53 |
| 11 Month Change | 10.26% |
| 3 Month Change | -11.03% |
| 1 Year Change | 3.20% |
| 33 Year Change | -79.36% |
| 5 Year Change | -89.02% |
| Change since IPO | -98.56% |
Recent News & Updates
Shareholder Returns
| COMBI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -5.8% | -5.8% | -2.1% |
| 1Y | 3.2% | 14.3% | 10.8% |
Return vs Industry: COMBI underperformed the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: COMBI underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| COMBI volatility | |
|---|---|
| COMBI Average Weekly Movement | 17.5% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: COMBI's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: COMBI's weekly volatility has increased from 12% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 9 | Peter Ekolind | www.combigene.com |
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures.
CombiGene AB (publ) Fundamentals Summary
| COMBI fundamental statistics | |
|---|---|
| Market cap | SEK 49.11m |
| Earnings (TTM) | -SEK 37.08m |
| Revenue (TTM) | SEK 3.15m |
16.2x
P/S Ratio-1.4x
P/E RatioIs COMBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COMBI income statement (TTM) | |
|---|---|
| Revenue | SEK 3.15m |
| Cost of Revenue | SEK 22.01m |
| Gross Profit | -SEK 18.86m |
| Other Expenses | SEK 18.22m |
| Earnings | -SEK 37.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -1.87 |
| Gross Margin | -599.71% |
| Net Profit Margin | -1,179.02% |
| Debt/Equity Ratio | 0% |
How did COMBI perform over the long term?
See historical performance and comparison